The report lists Molbio Diagnostics as a Focus Investment Idea with a Buy rating and 36% upside over a 1-year horizon.
Read this note →Molbio Diagnostics Limited
NSE MOLBIO BSE 544866 INE869T01028
0 filings · 0 analysed
1,333.00
-3.89%
over 5 days
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| Motilal Oswal Financial Services Ltd. (MOFSL) | 06 Oct 2026, 08:47 | long | 1,501.10 | 1,800.00 | 1,339.30 | -54% | open by 2027-10-06 |
| Motilal Oswal Financial Services Ltd (MOFSL) | 05 Oct 2026, 07:58 | long | 1,503.40 | 1,800.00 | 1,339.30 | -55% | open by 2027-10-05 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
Listed among one-year focus investment ideas at CMP Rs 1,498 with 20% upside.
Read this note →The report initiates coverage on Molbio Diagnostics with a BUY rating, CMP INR 1,503 and TP INR 1,800, citing its Truenat platform, 12,500+ devices in 90+ countries, and an estimated 23% revenue CAGR and 50% PAT CAGR over FY26-29.
Read this note →The initiating coverage section says Molbio's Truenat point-of-care molecular platform, with 12,500+ devices across 90+ countries and 43 assays, plus digital pathology expansion, should drive an estimated 23% revenue CAGR and 50% PAT CAGR over FY26-29, with 19% upside from CMP INR1,503.
Read this note →The report initiates coverage on Molbio Diagnostics with a BUY rating and a 12-month target price of INR1,800, implying about 19-21% upside, based on a 45x 12-month forward P/E (a 20% premium to the sector multiple of 36x), citing its differentiated R&D-driven business model and expected 23% revenue CAGR and 50% PAT CAGR over FY26-29E, while flagging customer concentration, high TB revenue dependence, regulatory delays and working-capital intensity as key risks.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief